Literature DB >> 15286709

Stability of nucleolar versus non-nucleolar forms of human p14(ARF).

Helen Rodway1, Susana Llanos, Janice Rowe, Gordon Peters.   

Abstract

Fusion proteins containing the amino-terminal domain of human p14(ARF) linked to green fluorescent protein are able to bind MDM2 and stabilize p53 without localization in the nucleolus. However, these fusion proteins are inherently unstable, with half-lives considerably shorter than either authentic ARF or chimaeras containing the entire coding domain, both of which are predominantly nucleolar. We present evidence that the unstable fusion proteins are significantly stabilized if redirected to the nucleolus by addition of a basic motif based on the nuclear localization signal of SV40 T-antigen. Moreover, the stability of these proteins can be enhanced by modulating the functions of MDM2 and p53. These data are consistent with a model in which ARF interacts with MDM2 in the nucleoplasm but is consequently subject to proteasomal degradation. Nucleolar localization may serve to store or stabilize ARF.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15286709     DOI: 10.1038/sj.onc.1207854

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  20 in total

Review 1.  The moving parts of the nucleolus.

Authors:  M O J Olson; Miroslav Dundr
Journal:  Histochem Cell Biol       Date:  2005-03-02       Impact factor: 4.304

2.  A novel ARF-binding protein (LZAP) alters ARF regulation of HDM2.

Authors:  Jialiang Wang; Xiaping He; Ying Luo; Wendell G Yarbrough
Journal:  Biochem J       Date:  2006-01-15       Impact factor: 3.857

3.  Regulation of NF-kappaB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor.

Authors:  Sonia Rocha; Michelle D Garrett; Kirsteen J Campbell; Katie Schumm; Neil D Perkins
Journal:  EMBO J       Date:  2005-03-10       Impact factor: 11.598

4.  Nucleophosmin (B23) targets ARF to nucleoli and inhibits its function.

Authors:  Chandrashekhar Korgaonkar; Jussara Hagen; Van Tompkins; April A Frazier; Chantal Allamargot; Frederick W Quelle; Dawn E Quelle
Journal:  Mol Cell Biol       Date:  2005-02       Impact factor: 4.272

5.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

6.  Loss of VHL promotes progerin expression, leading to impaired p14/ARF function and suppression of p53 activity.

Authors:  Youn-Sang Jung; Su-Jin Lee; Sun-Hye Lee; Ji-Yun Chung; Youn Jin Jung; Sang Hyun Hwang; Nam-Chul Ha; Bum-Joon Park
Journal:  Cell Cycle       Date:  2013-07-15       Impact factor: 4.534

Review 7.  Therapeutic targets in the ARF tumor suppressor pathway.

Authors:  Anthony J Saporita; Leonard B Maggi; Anthony J Apicelli; Jason D Weber
Journal:  Curr Med Chem       Date:  2007       Impact factor: 4.530

8.  Siva1 inhibits p53 function by acting as an ARF E3 ubiquitin ligase.

Authors:  Xingwu Wang; Meng Zha; Xiaocheng Zhao; Peng Jiang; Wenjing Du; Andrew Y H Tam; Yide Mei; Mian Wu
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

9.  Ubiquitylation on canonical and non-canonical sites targets the transcription factor neurogenin for ubiquitin-mediated proteolysis.

Authors:  Jonathan M D Vosper; Gary S McDowell; Christopher J Hindley; Christelle S Fiore-Heriche; Romana Kucerova; Ian Horan; Anna Philpott
Journal:  J Biol Chem       Date:  2009-03-31       Impact factor: 5.157

10.  Residues in the alternative reading frame tumor suppressor that influence its stability and p53-independent activities.

Authors:  Anne di Tommaso; Jussara Hagen; Van Tompkins; Viviane Muniz; Amel Dudakovic; Alain Kitzis; Veronique Ladeveze; Dawn E Quelle
Journal:  Exp Cell Res       Date:  2009-01-27       Impact factor: 3.905

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.